Elicera Therapeutics AB (publ) (STO:ELIC)

Market Cap	261.12M
Revenue (ttm)	4.31M
Net Income (ttm)	-18.75M
Shares Out	48.54M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,270
Average Volume	293,489
Open	5.39
Previous Close	5.45
Day's Range	5.26 - 5.53
52-Week Range	1.26 - 7.48
Beta	0.43
RSI	47.03
Earnings Date	Aug 29, 2025

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ELIC

Financial Performance

In 2024, Elicera Therapeutics AB's revenue was 7.13 million, a decrease of -36.52% compared to the previous year's 11.23 million. Losses were -16.11 million, -1.75% less than in 2023.